Join to View Full Profile
34 Park StRoom 518New Haven, CT 06519
Phone+1 203-974-7265
Dr. Fineberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 2010
Certifications & Licensure
CT State Medical License 2012 - 2026
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Ketamine in Borderline Personality Disorder Start of enrollment: 2018 Feb 15
- Measuring the Impact of Real Time fMRI Neurofeedback in Borderline Personality Disorder Start of enrollment: 2020 Nov 15
- Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder Start of enrollment: 2025 Mar 13
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Threading the needle: Practical considerations for merging theory-driven computational psychiatry with data-driven analytics to enhance precision health at scale.Annie Cheng, Anna Konova, Albert Powers, Philip Corlett, Ifat Levy
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. 2026-02-26 - Processes and Early Lessons From a Peer-Designed Recovery-Oriented Borderline Personality Disorder Online Support Group.Jillian Papa, Yujung Choi, Evan Nault, Sharon Nelson, Sarah K Fineberg
Personality and Mental Health. 2026-02-01 - A protocol for MIndfulness-based Neurofeedback to augment DBT psychotherapy for adults with Borderline Personality Disorder (MIND-BPD).Katherine G Jones, Marlee M Vandewouw, Jitendra Awasthi, Alexandra A Alario, Clemens Bauer
Plos One. 2026-01-01
Press Mentions
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025November 7th, 2025- ORYZON to Host Virtual KOL Event on July 9, 2025June 25th, 2025
- ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) PatientsJune 23rd, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
